MedTrace Logo

Unmasking the Prevalence of AC in an Unselected Echocardiographic Population

NCT04738266 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 381

Last updated 2021-02-04

No results posted yet for this study

Summary

This study will investigate the prevalence of echocardiographic red-flags of amyloid cardiomyopathy (AC) in patients undergoing clinically-indicated echocardiography (observational phase) and the prevalence of AC among AC-suggestive echocardiograms (interventional phase).

Conditions

  • Amyloid Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

Amyloid Cardiomyopathy

Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Trieste

    lead OTHER

Principal Investigators

  • Gianfranco Sinagra, MD, Full Professor · Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI) and University of Trieste

  • Claudio Rapezzi, MD, Full Professor · Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara - Ferrara

Eligibility

Min Age
55 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-01-20
Completion
2021-07-25

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04738266 on ClinicalTrials.gov